Abstract:Colorectal cancer (CRC) is the third most prevalent digestive tract cancer worldwide (9.7%), with a severe morbidity and mortality rate. The major therapeutic medications for CRC today are chemotherapy and targeted monoclonal antibodies, however, they all have drawbacks such as high cost, drug resistance, and substantial immunological adverse effects, and not all patients can benefit from them.
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.